Form 4: Abbott Laboratories Director Robert J. Alpern Acquires Stock Equivalent Units

Abbott Laboratories Director Robert J. Alpern acquired 57 stock equivalent units on June 30, 2025, as part of director compensation, increasing his total beneficial ownership to 10,195 units.

Summary

• Robert J. Alpern, a Director of Abbott Laboratories (ABT), acquired 57 stock equivalent units on June 30, 2025.
• These units were credited as director fees and are held in a stock equivalent unit account under a grantor trust.
• The stock equivalent units are designed to earn the same return as if the fees were invested directly in Abbott shares.
• Payment for these units is generally in cash at age 65 or upon retirement from the board.
• Following this transaction, Alpern's total beneficial ownership of stock equivalent units is 10,195.
• The reported balance of 10,195 units includes those acquired through a dividend reinvestment feature.
• The Form 4 filing was signed by Jessica H. Paik, Attorney-in-Fact, on July 1, 2025, under a Power of Attorney dated June 13, 2025.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction related to director compensation, which is a neutral event for company performance.

Positives

• Director compensation includes equity-linked units, which aligns director interests with shareholder value.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Acquisition of 57 stock equivalent units by Robert J. Alpern, a director, as part of his compensation for board service.

Stakeholder Impact

• Shareholders: The compensation of a director through equity-linked units helps align the director's financial interests with the long-term performance and value creation for shareholders.

Key Dates

Keywords

Abbott Laboratories, ABT, Form 4, Insider Transaction, Stock Equivalent Units, Director Compensation, Robert J. Alpern